Abstract CT275: A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)

Authors: Heinz-Josef Lenz, Benjamin Kuritzky, Anu Thummala, Stephan Kendall, Ravindranath Patel, Sreenivasa R. Chandana, Alisha H. Bent, Nancy Sherman, Ramanand Arun Subramanian, Fairooz Kabbinavar, Joel Randolph Hecht

Published: 2024-04-05

DOI: 10.1158/1538-7445.am2024-ct275

Source: Full article